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Abstract:              
Nano technology an exciting area of scientific development offers ways to create smaller, cheaper, lighter devices 
that can help to do better. The current literature has recognized and reported many possibility and applications of 
nano technology. The medical applications of nano technology are tremendous and could give medicine including 
the treatment of diabetes a new therapeutic approach. The frequency of diabetes is growing rapidly all over the 
globe at an alarming rate. Hence, the application of nano technology plays a very vital role in diabetes. Nano 
technology is useful in detection of even very minute amounts of insulin and blood sugar levels in the body. The 
treatment of diabetes includes proper delivery of insulin into blood stream which can be attained by nano 
technology by developing oral insulin which can make patient comfortable and patient compliance. Development of 
artificial pancreas can also be accomplished by using nano technology. Silicon boxes can also be implanted under 
the skin of diabetic patient that could temporarily restore the bodies’ glucose feedback loop. Without the need of 
powerful immunosuppressant’s that is acquired by nano technology. Another important approach of nano 
technology is a nano pump which injects insulin to the patient’s body at a constant rate balancing the amount of 
sugar in blood. And also can administer the small drug doses over a prolong period of time. Therefore, nano 
technology a new mode of treatment may help in making the everyday lives of millions of diabetics patients more 
tolerable. 
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INTRODUCTION: 
The application of nanotechnology to medicine is 
called nanomedicine, it is defined as: “Research and 
technology development at the atomic, molecular and 
macromolecular levels in the length scale of 
approximately 1 – 100 nanometer range, to provide a 
fundamental understanding of phenomena and 
materials at the nanoscale and to create and use 
structures, devices and systems that have novel 
properties and functions because of their small and/or 
intermediate size.” The size domains of components 
involved with nanotechnology are similar to 
that of biological structures. Because of this 
similarity in scale and certain functional properties, 
nanotechnology is a natural progression of many 
areas of health-related research such as synthetic and 
hybrid nanostructures that can sense and repair 
biological lesions and damages just as biological 
nanostructures (e.g. white-blood cells and wound-
healing molecules) [1]. 
 
DIABETES MILLETUS: 
Diabetes mellitus often referred to simply as 
diabetes.It is a syndrome of disordered metabolism, 
usually due to a combination of hereditary and 
environmental causes, resulting in abnormally high 
blood sugar levels (hyperglycemia). There are two 
major forms of diabetes: Type 1 and Type 2. Type2 
diabetes is commonly linked to obesity, which 
promotes insulin resistance [2]. In many obese 
individuals, insulin resistance is compensated for by 
increased insulin production, which can occur if there 
is an increase in β cell mass [3]. In approximately one 
third of obese individuals, there is a decreased cell 
mass caused by a marked increase in cell apoptosis, 
rendering these individuals Incapable of 
compensating for the insulin-resistant state. 
Similarly, type 1 diabetes is associated with a loss of 
beta cell mass, typically caused by autoimmune-
induced inflammation and apoptosis [4]. Thus, both 
type 1 and type 2 diabetes are negatively affected by 
the death of beta cells in the pancreas, resulting in 
inadequate insulin production. Long-term 
manifestations of diabetes include retinopathy, 
neuropathy, nephropathy, angiopathy, 
atherosclerosis, periodontitis, and other diabetic 
complications, such as impaired wound-healing. 
 
USE OF NANO TECHNOLOGY IN THE 
DETECTION OF BLOOD SUGAR AND 
INSULIN: 
 A new method that uses nanotechnology to rapidly 
measure minute amounts of insulin and blood sugar 
level. It can be achieved by following ways : 
 
 
 
By microphysiometer: 
The microphysiometer is built from multiwall carbon 
nanotubes, which are like several flat sheets of 
carbon atoms stacked and rolled into very small 
tubes. The nanotubes are electrically conductive and 
the concentration of insulin in the chamber can be 
directly related to the current at the electrode and the 
nanotubes operate reliably at pH levels characteristic 
of living cells. Current detection methods measure 
insulin production at intervals by periodically 
collecting small samples and measuring their insulin 
levels. The new sensor detects insulin levels 
continuously by measuring the transfer of electrons 
produced when insulin molecules oxidize in the 
presence of glucose. When the cells produce more 
insulin molecules, the current in the sensor increases 
and vice versa, allowing monitoring insulin 
concentrations in real time  [5]. 
 
By implantable sensor: 
Use of polyethylene glycol beads coated with 
fluorescent molecules to monitor diabetes 
Blood sugar levels are very effective in this method 
the beads are injected under the skin and stay in the 
interstitial fluid. When glucose in the interstitial fluid 
drops to dangerous levels, glucose displaces the 
fluorescent molecules and creates a glow. This glow 
is seen on a tattoo placed on the arm [1]. Sensor 
microchips are also being developed to continuously 
monitor key body parameters including pulse, 
temperature and blood glucose. A chip would be 
implanted under the skin and transmit a signal that 
could be monitored continuously.  
 
USE OF NANO TECHNOLOGY IN THE 
TREATMENT OF DIABETES:      
Diabetic patients control their blood-sugar levels via 
insulin introduced directly into the blood stream 
using injections. This unpleasant method is required 
since stomach acid destroys protein-based substances 
such as Insulin, making oral insulin consumption 
useless. The new          System is based on inhaling 
the insulin (instead of injecting it) and on a controlled 
release of insulin into the bloodstream (instead of 
manually controlling the amount of insulin injected) 
[6]. The treatment of diabetes includes the proper 
delivery of insulin in the blood stream which can be 
achieved by nanotechnology in the following ways:     
 
 Development of oral insulin: 
Production of pharmaceutically active proteins, such 
as insulin, in large quantities has become 
feasible[7,8].  
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The oral route is considered to be the most 
convenient and comfortable means for administration 
of insulin for less invasive and painless diabetes 
management, leading to a higher patient compliance 
[9]. Nevertheless, the intestinal epithelium is a major 
barrier to the absorption of hydrophilic drugs, as they 
cannot diffuse across epithelial cells through lipid-
bilayercell membranes to the bloodstream 
[10].Therefore, attention has been given to improving 
the paracellular transport of hydrophilic drugs [11, 
12]. A variety of intestinal permeation enhancers 
including chitosan (CS) have been used for the 
assistance of the absorption of hydrophilic 
macromolecules [13]. Therefore, a carrier system is 
needed to protect protein drugs from the harsh 
environment in the stomach and small intestine, if giv
en orally [14]. Additionally, CS nanoparticals (NPs) 
enhanced the intestinal absorption of protein 
molecules to a greater extent than aqueous solutions 
of CS in vivo [15]. The insulin loaded NPs coated 
with muco adhesive CS may prolong their residence 
in the small intestine, infiltrate into the mucus layer 
and subsequently mediate transiently opening the 
tight junctions between epithelial cells while 
becoming unstable and broken apart due to their 
pHsensitivity and/or degradability. The insulin 
released from the broken-apart NPs could then 
permeate through the paracellular pathway to the 
bloodstream, its ultimate destination. 
   
 Microsphere for oral insulin production: 
The most promising strategy to achieve oral insulin is 
the use of a microsphere system which is inherently a 
combination strategy. Microspheres act both as 
protease inhibitors by protecting the encapsulated 
insulin from enzymatic degradation within its matrix 
and as permeation enhancers by effectively crossing 
the epithelial layer after oral administration [16].  
 
Artificial pancreas 
Development of artificial pancreas could be the 
permanent solution for diabetic patients .The original 
idea was first described in 1974. The concept of its 
work is simple: A sensor electrode repeatedly 
measures the level of blood glucose; this information 
feeds into a small computer that energizes an infusion 
pump, and the needed units of insulin enter the 
bloodstream from a small reservoir [17]. Another 
way to restore body glucose is the use of a tiny 
silicon box that contains pancreatic beta cells taken 
from animals. The box is surrounded by a material 
with a very specific nanopore size (about 20 
nanometers in diameter). These pores are big enough 
to allow for glucose and insulin to pass through them, 
but small enough to impede the passage of much 
larger immune system molecules. These boxes can be 
implanted under the skin of diabetes patients. This 
could temporarily restore the body’s delicate glucose 
control feedback loop without the need of powerful 
immunosuppressant that can leave the patient at a 
serious risk of infection [18]. Scientists are also 
trying to create a nanorobot which would have 
insulin departed in inner chambers, and glucose level 
sensors on the surface. When blood glucose levels 
increase, the sensors on the surface would record it 
and insulin would be released. Yet, this kind of nano-
artificial pancreas is still only a theory [19]. 
 
 NANO PUMP: 
The nanopump is a powerful device and has many 
possible applications in the medical field. The first 
application of the pump, introduced by Debiotech, is 
Insulin delivery. The pump injects Insulin to the 
patient's body in a constant rate, balancing the 
amount of sugars in patients’ blood. The pump can 
also administer small drug doses over a long period 
of time [20]. 
 
CONCLUSION:                    
In the foreseeable future, the most important clinical 
application of nanotechnology will probably be in 
pharmaceutical development. Hopefully, the new 
kind of treatment may help in making the everyday 
lives of millions of diabetes patients more tolerable. 
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